Advertisement

Topics

Apoptosis Regulator BAX Bcl 2 Like Protein 4 or BCL2L4 or BAX Pipeline Review, H1 2018 [Report Updated: 22052018] Prices from USD $3500

06:34 EDT 11 Aug 2018 | BioPortfolio Report Blog

Apoptosis Regulator BAX Bcl 2 Like Protein 4 or BCL2L4 or BAX Pipeline Review, H1 2018


Summary


Apoptosis Regulator BAX Bcl 2 Like Protein 4 or BCL2L4 or BAX pipeline Target constitutes close to 6 molecules. Out of which approximately 2 molecules are developed by companies and remaining by the universities/institutes. The latest report Apoptosis Regulator BAX Pipeline Review, H1 2018, outlays comprehensive information on the Apoptosis Regulator BAX Bcl 2 Like Protein 4 or BCL2L4 or BAX targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.


Apoptosis Regulator BAX Bcl 2 Like Protein 4 or BCL2L4 or BAX Apoptosis regulator BAX or bcl2like protein 4 is a protein is encoded by the BAX gene. It accelerates programmed cell death by antagonizing the apoptosis repressor BCL2. It promotes activation of CASP3, and thereby apoptosis. It undergoes a conformation change that causes translocation to the mitochondrion membrane, leading to the release of cytochrome c that then triggers apoptosis under stress conditions.


The molecules developed by companies in Phase II and Preclinical stages are 1 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular and Central Nervous System which include indications Lung Cancer, Acute Ischemic Stroke, Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Huntington Disease, Liver Cancer, Melanoma, Multiple Sclerosis, Myocardial Infarction and Parkinson's Disease.


Furthermore, this report also reviews key players involved in Apoptosis Regulator BAX Bcl 2 Like Protein 4 or BCL2L4 or BAX targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope


The report provides a snapshot of the global therapeutic landscape for Apoptosis Regulator BAX Bcl 2 Like Protein 4 or BCL2L4 or BAX

The report reviews Apoptosis Regulator BAX Bcl 2 Like Protein 4 or BCL2L4 or BAX targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Apoptosis Regulator BAX Bcl 2 Like Protein 4 or BCL2L4 or BAX targeted therapeutics and enlists all their major and minor projects

The report assesses Apoptosis Regulator BAX Bcl 2 Like Protein 4 or BCL2L4 or BAX targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Apoptosis Regulator BAX Bcl 2 Like Protein 4 or BCL2L4 or BAX targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Apoptosis Regulator BAX Bcl 2 Like Protein 4 or BCL2L4 or BAX

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Apoptosis Regulator BAX Bcl 2 Like Protein 4 or BCL2L4 or BAX development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Apoptosis Regulator BAX Bcl 2 Like Protein 4 or BCL2L4 or BAX Pipeline Review, H1 2018 [Report Updated: 22052018] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "Apoptosis Regulator BAX Bcl 2 Like Protein 4 or BCL2L4 or BAX Pipeline Review, H1 2018 [Report Updated: 22052018] Prices from USD $3500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...